Recent Updates — RCUS
On October 21, 2026, Arcus Biosciences entered into an underwriting agreement to sell 14,285,715 shares of common stock at a public offering price of $17.50 per share. The company granted the underwriters an option to purchase up to an additional 2,142,857 shares. On October 23, 2026, the offering closed with the full exercise of the over-allotment option, resulting in the sale and issuance of 16,428,572 shares. The company received net proceeds of approximately $269.7 million after deducting underwriting discounts and estimated offering expenses. Arcus Biosciences operates in the biotechnology industry, focusing on the discovery and development of immunotherapies for cancer.
Arcus Biosciences estimates it held approximately $694.0 million in cash, cash equivalents, and marketable securities as of September 30, 2026. This figure is preliminary, unaudited, and subject to adjustment upon completion of financial closing procedures and management reviews. The company notes this estimate does not constitute a comprehensive statement of its financial results or condition for the period. Arcus Biosciences operates in the biotechnology industry, focusing on the discovery and development of immunotherapies.
On October 20, 2026, Arcus Biosciences presented new clinical data from its ARC-20 platform study evaluating casdatifan for clear cell renal cell carcinoma (ccRCC). In the second-line setting, casdatifan combined with cabozantinib demonstrated a median progression-free survival of 14.5 months and an 18-month overall survival rate of 77%. First-line TKI-free combinations showed high landmark PFS rates, while late-line monotherapy yielded a median overall survival of 35 months. The company operates in the biopharmaceutical industry, developing targeted cancer therapies.
Arcus Biosciences reported second-quarter 2026 financial results, posting a net loss of $91 million compared to break-even in the prior year period. Revenues declined to $41 million from $160 million due to the absence of a $143 million cumulative catch-up payment recognized in 2025 related to the pausing of the etrumadenant program. The company holds $775 million in cash and expects full-year revenue between $65 million and $75 million, with sufficient liquidity through at least the second half of 2028. Arcus announced three new clinical collaborations for its lead asset casdatifan involving Bristol Myers Squibb, Summit Therapeutics, and AVEO Oncology to evaluate combinations in clear cell renal cell carcinoma. Additionally, Gilead relinquished its three Board seats following the discontinuation of domvanalimab Phase 3 trials.